Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial
Authors:
Open Access
- 19 August 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (13) , 1837-1846
Abstract
Background Secondary resection of initially unresectable colorectal cancer liver metastases (CRLM) can prolong survival. The added value of selective internal radiotherapy (SIRT) to downsize lesions for resection is not known. This study evaluated the change in technical resectability of CRLM with the addition of SIRT to FOLFOX‐based chemotherapy. Methods Baseline and follow‐up hepatic imaging of patients who received modified FOLFOX (mFOLFOX6: fluorouracil, leucovorin, oxaliplatin) chemotherapy with or without bevacizumab (control arm) versus mFOLFOX6 (with or without bevacizumab) plus SIRT using yttrium‐90 resin microspheres (SIRT arm) in the phase III SIRFLOX trial were reviewed by three or five (of 14) expert hepatopancreatobiliary surgeons for resectability. Reviewers were blinded to one another, treatment assignment, extrahepatic disease status, and information on clinical and scanning time points. Technical resectability was defined as at least 60 per cent of reviewers (3 of 5, or 2 of 3) assessing a patient's liver metastases as surgically removable. Results Some 472 patients were evaluable (SIRT, 244; control, 228). There was no significant baseline difference in the proportion of technically resectable liver metastases between SIRT (29, 11·9 per cent) and control (25, 11·0 per cent) arms (P = 0·775). At follow‐up, significantly more patients in both arms were deemed technically resectable compared with baseline: 159 of 472 (33·7 per cent) versus 54 of 472 (11·4 per cent) respectively (P = 0·001). More patients were resectable in the SIRT than in the control arm: 93 of 244 (38·1 per cent) versus 66 of 228 (28·9 per cent) respectively (P < 0·001). Conclusion Adding SIRT to chemotherapy may improve the resectability of unresectable CRLM.Keywords
This publication has 32 references indexed in Scilit:
- Cause of Death from Liver Metastases in Colorectal CancerAnnals of Surgical Oncology, 2013
- Ten-Year Survival after Liver Resection for Colorectal Metastases: Systematic Review and Meta-AnalysisISRN Oncology, 2011
- Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment GroupEuropean Journal of Cancer, 2007
- Towards a pan-European consensus on the treatment of patients with colorectal liver metastasesEuropean Journal of Cancer, 2006
- Treatment of liver metastases of colorectal cancerAnnals of Oncology, 2005
- Short- and-long term results of intraoperative radiofrequency ablation of liver metastasesInternational Journal of Colorectal Disease, 2005
- Predictors of Survival After Radiofrequency Thermal Ablation of Colorectal Cancer Metastases to the Liver: A Prospective StudyJournal of Clinical Oncology, 2005
- Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by ChemotherapyAnnals of Surgery, 2004
- Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] MetastasesAnnals of Surgical Oncology, 2001
- Comparison of Histologic and Colposcopic Findings in Des-Exposed FemalesAnnals of Surgery, 1979